Literature DB >> 34045467

MicroRNA-200c restoration reveals a cytokine profile to enhance M1 macrophage polarization in breast cancer.

Michelle M Williams1, Jessica L Christenson1, Kathleen I O'Neill1, Sabrina A Hafeez1, Claire L Ihle1, Nicole S Spoelstra1, Jill E Slansky2, Jennifer K Richer3.   

Abstract

Many immune suppressive mechanisms utilized by triple negative breast cancer (TNBC) are regulated by oncogenic epithelial-to-mesenchymal transition (EMT). How TNBC EMT impacts innate immune cells is not fully understood. To determine how TNBC suppresses antitumor macrophages, we used microRNA-200c (miR-200c), a powerful repressor of EMT, to drive mesenchymal-like mouse mammary carcinoma and human TNBC cells toward a more epithelial state. MiR-200c restoration significantly decreased growth of mouse mammary carcinoma Met-1 cells in culture and in vivo. Cytokine profiling of Met-1 and human BT549 cells revealed that miR-200c upregulated cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), promoted M1 antitumor macrophage polarization. Cytokines upregulated by miR-200c correlated with an epithelial gene signature and M1 macrophage polarization in BC patients and predicted a more favorable overall survival for TNBC patients. Our findings demonstrate that immunogenic cytokines (e.g., GM-CSF) are suppressed in aggressive TNBC, warranting further investigation of cytokine-based therapies to limit disease recurrence.

Entities:  

Year:  2021        PMID: 34045467     DOI: 10.1038/s41523-021-00273-1

Source DB:  PubMed          Journal:  NPJ Breast Cancer        ISSN: 2374-4677


  75 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.

Authors:  Min Hye Jang; Hyun Jeong Kim; Eun Joo Kim; Yul Ri Chung; So Yeon Park
Journal:  Hum Pathol       Date:  2015-05-30       Impact factor: 3.466

3.  Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas.

Authors:  Anushka Dongre; Mohammad Rashidian; Ferenc Reinhardt; Aaron Bagnato; Zuzana Keckesova; Hidde L Ploegh; Robert A Weinberg
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

4.  A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.

Authors:  Milena P Mak; Pan Tong; Lixia Diao; Robert J Cardnell; Don L Gibbons; William N William; Ferdinandos Skoulidis; Edwin R Parra; Jaime Rodriguez-Canales; Ignacio I Wistuba; John V Heymach; John N Weinstein; Kevin R Coombes; Jing Wang; Lauren Averett Byers
Journal:  Clin Cancer Res       Date:  2015-09-29       Impact factor: 12.531

Review 5.  Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis.

Authors:  Wei Lu; Yibin Kang
Journal:  Dev Cell       Date:  2019-05-06       Impact factor: 12.270

Review 6.  Epithelial to mesenchymal transition and breast cancer.

Authors:  Eva Tomaskovic-Crook; Erik W Thompson; Jean Paul Thiery
Journal:  Breast Cancer Res       Date:  2009-11-09       Impact factor: 6.466

7.  Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.

Authors:  Min Yu; Aditya Bardia; Ben S Wittner; Shannon L Stott; Malgorzata E Smas; David T Ting; Steven J Isakoff; Jordan C Ciciliano; Marissa N Wells; Ajay M Shah; Kyle F Concannon; Maria C Donaldson; Lecia V Sequist; Elena Brachtel; Dennis Sgroi; Jose Baselga; Sridhar Ramaswamy; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran
Journal:  Science       Date:  2013-02-01       Impact factor: 47.728

8.  Direct and Indirect Regulators of Epithelial-Mesenchymal Transition-Mediated Immunosuppression in Breast Carcinomas.

Authors:  Anushka Dongre; Mohammad Rashidian; Elinor Ng Eaton; Ferenc Reinhardt; Prathapan Thiru; Maria Zagorulya; Sunita Nepal; Tuba Banaz; Anna Martner; Stefani Spranger; Robert A Weinberg
Journal:  Cancer Discov       Date:  2020-12-16       Impact factor: 39.397

9.  ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types.

Authors:  Waltraut Lehmann; Dirk Mossmann; Julia Kleemann; Kerstin Mock; Chris Meisinger; Tilman Brummer; Ricarda Herr; Simone Brabletz; Marc P Stemmler; Thomas Brabletz
Journal:  Nat Commun       Date:  2016-02-15       Impact factor: 14.919

Review 10.  Epithelial-mesenchymal plasticity in carcinoma metastasis.

Authors:  Jeff H Tsai; Jing Yang
Journal:  Genes Dev       Date:  2013-10-15       Impact factor: 11.361

View more
  8 in total

1.  Tumor-associated macrophages of the M1/M2 phenotype are involved in the regulation of malignant biological behavior of breast cancer cells through the EMT pathway.

Authors:  Zhuo Chen; Jing Wu; Liang Wang; Hua Zhao; Jie He
Journal:  Med Oncol       Date:  2022-05-16       Impact factor: 3.064

2.  Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer.

Authors:  Zheqi Li; Nicole S Spoelstra; Matthew J Sikora; Sharon B Sams; Anthony Elias; Jennifer K Richer; Adrian V Lee; Steffi Oesterreich
Journal:  NPJ Breast Cancer       Date:  2022-05-10

3.  Neural regulations of the tumor microenvironment.

Authors:  Anthony C Restaino; Paola D Vermeer
Journal:  FASEB Bioadv       Date:  2021-09-12

Review 4.  Non-Coding RNAs in the Crosstalk between Breast Cancer Cells and Tumor-Associated Macrophages.

Authors:  Anna Benedetti; Chiara Turco; Giulia Fontemaggi; Francesco Fazi
Journal:  Noncoding RNA       Date:  2022-02-06

5.  Elevated Expression of miR-200c/141 in MDA-MB-231 Cells Suppresses MXRA8 Levels and Impairs Breast Cancer Growth and Metastasis In Vivo.

Authors:  Kaitlyn E Simpson; Katrina L Watson; Roger A Moorehead
Journal:  Genes (Basel)       Date:  2022-04-14       Impact factor: 4.141

6.  Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8+ T Cell Immunity.

Authors:  Faye A Camp; Tonya M Brunetti; Michelle M Williams; Jessica L Christenson; Varsha Sreekanth; James C Costello; Zachary L Z Hay; Ross M Kedl; Jennifer K Richer; Jill E Slansky
Journal:  Cancers (Basel)       Date:  2022-09-09       Impact factor: 6.575

Review 7.  The role of miR-200 family in the regulation of hallmarks of cancer.

Authors:  Klaudia Klicka; Tomasz M Grzywa; Aleksandra Mielniczuk; Alicja Klinke; Paweł K Włodarski
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

8.  LARRPM restricts lung adenocarcinoma progression and M2 macrophage polarization through epigenetically regulating LINC00240 and CSF1.

Authors:  Yue Li; Chen Chen; Hai-Lin Liu; Zhen-Fa Zhang; Chang-Li Wang
Journal:  Cell Mol Biol Lett       Date:  2022-10-11       Impact factor: 8.702

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.